These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 26569595)

  • 1. Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice.
    Uchida T; Hiraga N; Imamura M; Yoshimi S; Kan H; Miyaki E; Tsuge M; Abe H; Hayes CN; Aikata H; Ishida Y; Tateno C; Ellis JD; Chayama K
    Virus Res; 2016 Feb; 213():62-68. PubMed ID: 26569595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice.
    Shi N; Hiraga N; Imamura M; Hayes CN; Zhang Y; Kosaka K; Okazaki A; Murakami E; Tsuge M; Abe H; Aikata H; Takahashi S; Ochi H; Tateno-Mukaidani C; Yoshizato K; Matsui H; Kanai A; Inaba T; McPhee F; Gao M; Chayama K
    Gut; 2013 Jul; 62(7):1055-61. PubMed ID: 23322441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo.
    Abe H; Imamura M; Hiraga N; Tsuge M; Mitsui F; Kawaoka T; Takahashi S; Ochi H; Maekawa T; Hayes CN; Tateno C; Yoshizato K; Murakami S; Yamashita N; Matsuhira T; Asai K; Chayama K
    J Hepatol; 2011 Jul; 55(1):11-8. PubMed ID: 21145867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.
    Lawitz E; Sulkowski M; Jacobson I; Kraft WK; Maliakkal B; Al-Ibrahim M; Gordon SC; Kwo P; Rockstroh JK; Panorchan P; Miller M; Caro L; Barnard R; Hwang PM; Gress J; Quirk E; Mobashery N
    Antiviral Res; 2013 Sep; 99(3):214-20. PubMed ID: 23747481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing.
    Abe H; Hayes CN; Hiraga N; Imamura M; Tsuge M; Miki D; Takahashi S; Ochi H; Chayama K
    Am J Gastroenterol; 2013 Sep; 108(9):1464-72. PubMed ID: 23896953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice.
    Osawa M; Uchida T; Imamura M; Teraoka Y; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Ishida Y; Tateno C; Miyayama Y; Hijikata M; Chayama K
    J Gen Virol; 2019 Jul; 100(7):1123-1131. PubMed ID: 31199224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus.
    Hamana A; Takahashi Y; Uchida T; Nishikawa M; Imamura M; Chayama K; Takakura Y
    Antiviral Res; 2017 Oct; 146():130-138. PubMed ID: 28864074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis.
    Barnard RJ; McHale CM; Newhard W; Cheney CA; Graham DJ; Himmelberger AL; Strizki J; Hwang PM; Rivera AA; Reeves JD; Nickle D; Dinubile MJ; Hazuda DJ; Mobashery N
    Virology; 2013 Sep; 443(2):278-84. PubMed ID: 23763767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice.
    Ohya K; Imamura M; Teraoka Y; Uchida T; Fujino H; Nakahara T; Ono A; Murakami E; Yamauchi M; Kawaoka T; Miki D; Tsuge M; Abe-Chayama H; Hayes CN; Aikata H; Ishida Y; Tateno C; Song H; Miyayama Y; Hijikata M; Chayama K
    Biochem Biophys Res Commun; 2021 Jun; 559():78-83. PubMed ID: 33932902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice.
    Kan H; Hiraga N; Imamura M; Hayes CN; Uchida T; Miyaki E; Tsuge M; Abe H; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
    Antivir Ther; 2016; 21(4):307-15. PubMed ID: 26562322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.
    Wang C; Huang H; Valera L; Sun JH; O'Boyle DR; Nower PT; Jia L; Qiu D; Huang X; Altaf A; Gao M; Fridell RA
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1350-8. PubMed ID: 22214777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of successful treatment with telaprevir-based triple therapy for hepatitis C infection after treatment failure with vaniprevir-based triple therapy.
    Takayama K; Furusyo N; Ogawa E; Shimizu M; Hiramine S; Mitsumoto F; Ura K; Toyoda K; Murata M; Hayashi J
    J Infect Chemother; 2014 Sep; 20(9):577-81. PubMed ID: 25000830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis.
    Rodriguez-Torres M; Stoehr A; Gane EJ; Serfaty L; Lawitz E; Zhou A; Bourque M; Bhanja S; Strizki J; Barnard RJ; Hwang PM; DiNubile MJ; Mobashery N
    Clin Gastroenterol Hepatol; 2014 Jun; 12(6):1029-37.e5. PubMed ID: 24120953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HCV evolutionary genetics of SVR versus virologic failure assessed from the vaniprevir phase III registration trials.
    Ludmerer SW; Hirano T; Black S; Howe AY; Chang W; Takase A; Nakamura K; Tanaka Y; Kumada H; Hayashi N; Nickle D
    Antiviral Res; 2016 Jun; 130():118-29. PubMed ID: 26947564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies.
    Kumada H; Mochida S; Suzuki F; Chayama K; Karino Y; Nakamura K; Fujimoto G; Howe AY; Ludmerer SW; Mobashery N
    J Gastroenterol Hepatol; 2016 Oct; 31(10):1674-1683. PubMed ID: 26936417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
    Xue W; Ban Y; Liu H; Yao X
    J Chem Inf Model; 2014 Feb; 54(2):621-33. PubMed ID: 23745769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study.
    Hayashi N; Nakamuta M; Takehara T; Kumada H; Takase A; Howe AY; Ludmerer SW; Mobashery N
    J Gastroenterol; 2016 Apr; 51(4):390-403. PubMed ID: 26403160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic lipophilic antioxidant BO-653 suppresses HCV replication.
    Yasui F; Sudoh M; Arai M; Kohara M
    J Med Virol; 2013 Feb; 85(2):241-9. PubMed ID: 23192857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice.
    Ohara E; Hiraga N; Imamura M; Iwao E; Kamiya N; Yamada I; Kono T; Onishi M; Hirata D; Mitsui F; Kawaoka T; Tsuge M; Takahashi S; Abe H; Hayes CN; Ochi H; Tateno C; Yoshizato K; Tanaka S; Chayama K
    J Hepatol; 2011 May; 54(5):872-8. PubMed ID: 21145818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A serine palmitoyltransferase inhibitor blocks hepatitis C virus replication in human hepatocytes.
    Katsume A; Tokunaga Y; Hirata Y; Munakata T; Saito M; Hayashi H; Okamoto K; Ohmori Y; Kusanagi I; Fujiwara S; Tsukuda T; Aoki Y; Klumpp K; Tsukiyama-Kohara K; El-Gohary A; Sudoh M; Kohara M
    Gastroenterology; 2013 Oct; 145(4):865-73. PubMed ID: 23791700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.